RxDoctor Payments Data

Syed Iqbal, MD

Cardiovascular Disease · Gloversville, NYNPI 1235193087

Payments from drug & device makers

$2,772in general payments, 2019–2025

Across 170 payments — averaging $16.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$428
  • Johnson & Johnson$420
  • Biotronik Inc.$308
  • Pfizer$204
  • Amarin Pharma, Inc.$187
  • Bayer$128
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$2,69697%
  • Education$763%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,772 in reported general payments places this provider in the 60th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$138,504
Medicare patients
900
Services billed
2,485

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin539$476,020
EliquisApixaban365$378,815
OzempicSemaglutide322$346,944
EntrestoSacubitril/Valsartan328$281,643
FarxigaDapagliflozin Propanediol274$201,884
Repatha SureclickEvolocumab169$152,948
XareltoRivaroxaban165$146,420
CorlanorIvabradine Hcl64$47,436
MounjaroTirzepatide26$28,227
Dofetilide80$26,958
MultaqDronedarone Hcl33$26,539
BrilintaTicagrelor23$24,740
VascepaIcosapent Ethyl47$21,781
Varenicline Tartrate87$19,653
Praluent PenAlirocumab36$17,275

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$115$476,020539 claims
PfizerEliquis$204$378,815365 claims
Novo NordiskOzempic$73$346,944322 claims
NovartisEntresto$120$281,643328 claims
AstraZenecaFarxiga, Brilinta$428$226,623297 claims
Johnson & JohnsonXarelto$420$146,420165 claims
AmgenCorlanor$77$47,43664 claims
Sanofi-aventis U.S. LLCMultaq$51$26,53933 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Gloversville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →